OBJECTIVES: Estimate the Budget Impact of the adoption of new Axitinib (Caxetib^®) as a second line therapy for a cohort of 171 patients diagnosed with metastatic renal cell carcinoma (mRCC) at the Mexican Social Security Institute (IMSS) in Mexico.

METHODS: A 5-year Budget Impact Analysis (BIA) model was developed to estimate the incremental BI for 171 patients in treatment for 2^nd line mRCC at the IMSS with the adoption of new Axitinib (Caxetib^®), compared to basal axitinib, sorafenib, everolimus and cabozantinib. The epidemiological data was taken from GLOBOCAN 2020. Costs were obtained from public sources. BIA assumptions include that new Axitinib (Caxetib^®) would gradually gain market share until it reaches 100% of new or switching patients in the fifth year. All costs are in 2024 USD. BIA based on 2 scenarios (current without new Axitinib vs new scenario considering new Axitinib)

RESULTS: Annual per patient pharmacological costs were $4,432.49 new Axitinib (Caxetib^®), for basal Axitinib $6,332.13 ($1,899.64 more expensive than new Axitinib), for everolimus $6,725.57 and cabozantinib $14,432.70. For every patient treated with new Axitinib (Caxetib^®), IMSS saves an average of $9,137.47. Results were robust according to the sensitivity analysis. Savings with an average predicted five-year impact reached $286,22 for 171 patient cohort.

CONCLUSIONS: Results of 171 cohort BIA treated at IMSS, conclu­ded that the adoption of new Axitinib (Caxetib^®) has a positive impact on its budget (leads to important savings), considering the low cost when compared to other 2^nd line mRCC.